TP53 Arg72Pro polymorphism is associated with esophageal cancer risk: A meta-analysis

Table 3 Results of meta-analysis for TP53 Arg72Pro polymorphism and esophageal cancer risk

Study groups	n1	Sample size(case/control)	Arg/Arg vs Pro/Pro			Arg/Arg+Arg/Pro vs Pro/Pro			Arg/Arg vs Arg/Pro+Pro/Pro
			OR (95% CI)	P2	P3	OR (95% CI)	P2	P3	OR (95% CI)	P2	P3
Total	9	2114/3431	0.76 (0.54-1.07)4	0.114	0.001	0.73 (0.57-0.94)4	0.014	0.009	0.89 (0.69-1.13)4	0.334	0.004
Source of controls
Population	5	1787/2690	0.56 (0.47-0.66)	< 0.001	0.273	0.57 (0.50-0.66)	< 0.001	0.404	0.80 (0.70-0.92)	0.001	0.324
Population/blood donors	1	62/131	2.33 (1.03-5.24)	0.041	-	1.25 (0.61-2.54)	0.538	-	2.71 (1.42-5.20)	0.003	-
Hospital	2	119/495	0.70 (0.22-2.18)4	0.533	0.022	0.80 (0.37-2.04)4	0.754	0.051	0.69 (0.36-1.31)4	0.252	0.08
Unknown	1	73/115	2.25 (0.73-6.91)	0.157	-	2.20 (0.77-6.28)	0.142	-	1.17 (0.63-2.16)	0.626	-
Specimen of cases
White blood cells or normal tissue	6	1947/3128	0.56 (0.47-0.65)	< 0.001	0.233	0.58 (0.51-0.67)	< 0.001	0.219	0.78 (0.68-0.88)	< 0.001	0.321
White blood cells/tumor tissue	1	73/115	2.25 (0.73-6.91)	0.157	-	2.20 (0.77-6.28)	0.142	-	1.17 (0.63-2.16)	0.626	-
Tumor tissue	1	62/131	2.33 (1.03-5.24)	0.041	-	1.25 (0.61-2.54)	0.538	-	2.71 (1.42-5.20)	0.003	-
Exfoliated esophageal cells	1	32/57	1.94 (0.59-6.38)	0.275	-	1.39 (0.56-3.41)	0.474	-	1.78 (0.61-5.19)	0.292	-
Sample size
≥ 200 subjects	6	1947/3128	0.56 (0.47-0.65)	< 0.001	0.233	0.58 (0.51-0.67)	< 0.001	0.219	0.78 (0.68-0.88)	< 0.001	0.321
< 200 subjects	3	167/303	2.21 (1.24-3.93)	0.007	0.969	1.47 (0.90-2.40)	0.121	0.677	1.73 (1.15-2.61)	0.009	0.182

¹Number of comparisons; ²P value for the association; ³P value for the heterogeneity;

⁴Random effects model was used when P value for heterogeneity test < 0.1, otherwise, fixed-effects model was used. Arg: Arginine; Pro: Proline; OR: Odds ratio.